Trial Overview
NCT ID: NCT07706478 Phase: N/A Enrollment Target: 120 Status: Recruiting
Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.
Why This Matters
[Draft — editorial context needed]
Source
Original Publication
ClinicalTrials.gov
